<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352922</url>
  </required_header>
  <id_info>
    <org_study_id>691275</org_study_id>
    <nct_id>NCT02352922</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy</brief_title>
  <official_title>A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AdventHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AdventHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are studying ways to improve pain control after surgery. One way to&#xD;
      decrease pain is to inject incisions with a numbing medicine (local anesthetic) while in the&#xD;
      operating room. There is an FDA approved extended-release version of a commonly used local&#xD;
      anesthetic (bupivacaine) that can last for 4 days instead of 6 hours. The investigators are&#xD;
      studying whether using the extended-release medication (Exparel) will give better pain relief&#xD;
      after laparoscopic and robotic-assisted hysterectomies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lidocaine and bupivacaine hydrochloride (HCl) are the most commonly used drugs for wound&#xD;
      infiltration during laparoscopic surgery for post-operative pain control. There is some&#xD;
      evidence that wound infiltration decreases immediate post-operative pain. While bupivacaine&#xD;
      has a slightly slower onset of action (5-10 minutes), it has become the preferred injectable&#xD;
      anesthetic for surgical use because of its longer duration of effect (4-8 hours versus 1-2&#xD;
      hours for lidocaine).&#xD;
&#xD;
      DepoFoam bupivacaine (EXPAREL, Pacira Pharmaceuticals, Inc., Parsippany, NJ, USA) is a newer&#xD;
      extended-release formulation of bupivacaine HCl approved by the U.S. Federal Drug&#xD;
      Administration in October 2011. In this suspension, bupivacaine is encapsulated in&#xD;
      microscopic spherical lipid-based particles of varying size to allow dispersion of the drug&#xD;
      over an extended period of time. Analgesia is prolonged up to 96 hours. Given the extended&#xD;
      duration of action, this liposomal bupivacaine may be better at providing post-operative pain&#xD;
      relief in laparoscopic surgery.&#xD;
&#xD;
      Phase three trials have shown better pain control in the first 24 hours and less opioid use&#xD;
      overall in bunionectomies, hemorrhoidectomies, and total knee replacement surgery when&#xD;
      compared to placebo. No studies, however, have been published evaluating extended-release&#xD;
      liposomal bupivacaine for laparoscopic surgery, or gynecologic surgery in general. Currently,&#xD;
      we are using liposomal bupivacaine for pain relief after laparoscopic hysterectomies, but as&#xD;
      stated, it has never been formally evaluated.&#xD;
&#xD;
      We hypothesize that liposomal bupivacaine (&quot;extended-release&quot;) provides extended pain relief&#xD;
      and decreases the need for supplemental opioid use after major laparoscopic surgery. We will&#xD;
      be evaluating whether pre-incision infiltration of extended-release bupivacaine decreases&#xD;
      post-operative pain from laparoscopic and robotic-assisted hysterectomy compared to&#xD;
      bupivacaine HCl (&quot;short-acting&quot;). To achieve this evaluation we designed a double-blinded&#xD;
      randomized controlled trial.&#xD;
&#xD;
      Patients who are scheduled to undergo a laparoscopic or robotic-assisted hysterectomy will be&#xD;
      invited to participate. Group A will receive pre-incision infiltration of each trocar site&#xD;
      with 4 ml of 0.25% Bupivacaine HCl. Group B will receive pre-incision infiltration of each&#xD;
      trocar site with 4 ml of extended-release bupivacaine (EXPAREL) (13.3mg/ml). Subjects and&#xD;
      outcome assessors will be blinded to group allocation.&#xD;
&#xD;
      Data will be collected while patients are in the hospital on pain levels and consumption of&#xD;
      opioid pain medications. Upon discharge, pain levels, functioning, and quantity of opioid and&#xD;
      non-steroidal anti-inflammatory (NSAID) pain medications will be collected through online&#xD;
      questionnaires. Subjects will be followed until their 2-3 weeks post-operative visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) Post-operative Pain Score on Post-Operative Day 1 (POD1).</measure>
    <time_frame>24 hours</time_frame>
    <description>Numerical Rating Scale (0-10) post-operative pain score on POD1, where 0 = no pain and 10 = worst pain imaginable</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score at 2 Hours</measure>
    <time_frame>2 hours post-op</time_frame>
    <description>numeric rating scale (0-10), mean and SD, where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score at 4 Hours</measure>
    <time_frame>4 hours post-op</time_frame>
    <description>Pain scale measured from 0-10, where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score at 8 Hours</measure>
    <time_frame>8 hours post-op</time_frame>
    <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score at 16 Hours</measure>
    <time_frame>16 hours post-op</time_frame>
    <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score Post-op Day 2</measure>
    <time_frame>2 days post-op</time_frame>
    <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score Post-op Day 3</measure>
    <time_frame>3 days post-op</time_frame>
    <description>Pain scale, where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRS Pain Score Post-op Day 14</measure>
    <time_frame>Post-Operative Day 14</time_frame>
    <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Post-Operative Day 2</time_frame>
    <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Post-Operative Day 3</time_frame>
    <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as Measured by the Brief Pain Inventory (BPI)</measure>
    <time_frame>Post-Operative Day 14</time_frame>
    <description>at time of post-op visit The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Use Prior to Hospital Discharge</measure>
    <time_frame>24 hours</time_frame>
    <description>Oral morphine equivalent of opioid use while in the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Use End of Post-op Day 3</measure>
    <time_frame>72 hrs post-op</time_frame>
    <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid Use at Post-op Day 14</measure>
    <time_frame>Post-Operative Day 14</time_frame>
    <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Post-Operative Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Surgical Procedure, Unspecified</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>extended-release bupivacaine (EXPAREL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>short-acting bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>pre-incision infiltration with liposomal bupivacaine</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl</intervention_name>
    <description>pre-incision infiltration with bupivacaine HCl</description>
    <arm_group_label>Bupivacaine HCl</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Benign indication for surgery&#xD;
&#xD;
          2. Planned multiport laparoscopic or robotic assisted hysterectomy&#xD;
&#xD;
          3. Non-pregnant&#xD;
&#xD;
          4. Able to provide informed consent&#xD;
&#xD;
          5. Owns smartphone or computer with internet access&#xD;
&#xD;
          6. Willing to provide contact phone number and accept SMS text messages&#xD;
&#xD;
          7. Ability to speak and read English (because texts and online surveys will be in English&#xD;
             only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Planned additional procedures (e.g. incontinence surgery, prolapse repair or bowel&#xD;
             surgery)&#xD;
&#xD;
          2. Contraindication to study drug&#xD;
&#xD;
               1. Severe Hepatic disease&#xD;
&#xD;
               2. Severe Kidney disease&#xD;
&#xD;
               3. Current use of monoamine oxidase inhibitors&#xD;
&#xD;
               4. Current use of tricyclic antidepressants&#xD;
&#xD;
          3. History of substance or alcohol abuse within the past 2 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgine Lamvu, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital Orlando</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kenneth I Barron, MD</last_name>
    <role>Study Director</role>
    <affiliation>Florida Hospital Orlando</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saleh A, Fox G, Felemban A, Guerra C, Tulandi T. Effects of local bupivacaine instillation on pain after laparoscopy. J Am Assoc Gynecol Laparosc. 2001 May;8(2):203-6.</citation>
    <PMID>11342725</PMID>
  </reference>
  <reference>
    <citation>Ke RW, Portera SG, Bagous W, Lincoln SR. A randomized, double-blinded trial of preemptive analgesia in laparoscopy. Obstet Gynecol. 1998 Dec;92(6):972-5.</citation>
    <PMID>9840560</PMID>
  </reference>
  <reference>
    <citation>Loizides S, Gurusamy KS, Nagendran M, Rossi M, Guerrini GP, Davidson BR. Wound infiltration with local anaesthetic agents for laparoscopic cholecystectomy. Cochrane Database Syst Rev. 2014 Mar 12;(3):CD007049. doi: 10.1002/14651858.CD007049.pub2. Review.</citation>
    <PMID>24619479</PMID>
  </reference>
  <reference>
    <citation>Bergese SD, Onel E, Portillo J. Evaluation of DepoFoam(®) bupivacaine for the treatment of postsurgical pain. Pain Manag. 2011 Nov;1(6):539-47. doi: 10.2217/pmt.11.62.</citation>
    <PMID>24645765</PMID>
  </reference>
  <reference>
    <citation>Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011 Sep;28(9):776-88. doi: 10.1007/s12325-011-0052-y. Epub 2011 Aug 12.</citation>
    <PMID>21842428</PMID>
  </reference>
  <reference>
    <citation>Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011 Dec;54(12):1552-9. doi: 10.1097/DCR.0b013e318232d4c1.</citation>
    <PMID>22067185</PMID>
  </reference>
  <reference>
    <citation>Bramlett K, Onel E, Viscusi ER, Jones K. A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. Knee. 2012 Oct;19(5):530-6. doi: 10.1016/j.knee.2011.12.004. Epub 2012 Jan 28.</citation>
    <PMID>22285545</PMID>
  </reference>
  <reference>
    <citation>Kato J, Ogawa S, Katz J, Nagai H, Kashiwazaki M, Saeki H, Suzuki H. Effects of presurgical local infiltration of bupivacaine in the surgical field on postsurgical wound pain in laparoscopic gynecologic examinations: a possible preemptive analgesic effect. Clin J Pain. 2000 Mar;16(1):12-7.</citation>
    <PMID>10741813</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <results_first_submitted>April 10, 2018</results_first_submitted>
  <results_first_submitted_qc>September 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2020</results_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laparoscopy</keyword>
  <keyword>Robotic Surgical Procedures</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Anesthetics, Local</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Pain, Postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available, but aggregate data can be made available to interested correspondents</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine</title>
          <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine HCl</title>
          <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28">completed POD14 Survey</participants>
                <participants group_id="P2" count="28">Completed POD14 survey</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine</title>
          <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine HCl</title>
          <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="8.6"/>
                    <measurement group_id="B2" value="45.4" spread="9.1"/>
                    <measurement group_id="B3" value="45.19" spread="8.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="19.8" upper_limit="83.9"/>
                    <measurement group_id="B2" value="27.6" lower_limit="19.3" upper_limit="43.7"/>
                    <measurement group_id="B3" value="28.3" lower_limit="19.3" upper_limit="83.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale (NRS) Post-operative Pain Score on Post-Operative Day 1 (POD1).</title>
        <description>Numerical Rating Scale (0-10) post-operative pain score on POD1, where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (NRS) Post-operative Pain Score on Post-Operative Day 1 (POD1).</title>
          <description>Numerical Rating Scale (0-10) post-operative pain score on POD1, where 0 = no pain and 10 = worst pain imaginable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="2.2"/>
                    <measurement group_id="O2" value="4.97" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score at 2 Hours</title>
        <description>numeric rating scale (0-10), mean and SD, where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>2 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score at 2 Hours</title>
          <description>numeric rating scale (0-10), mean and SD, where 0 = no pain and 10 = worst pain imaginable</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="2.53"/>
                    <measurement group_id="O2" value="2.74" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score at 4 Hours</title>
        <description>Pain scale measured from 0-10, where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>4 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score at 4 Hours</title>
          <description>Pain scale measured from 0-10, where 0 = no pain and 10 = worst pain imaginable</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="2.86"/>
                    <measurement group_id="O2" value="3" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score at 8 Hours</title>
        <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>8 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score at 8 Hours</title>
          <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="2.75"/>
                    <measurement group_id="O2" value="3.67" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score at 16 Hours</title>
        <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>16 hours post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score at 16 Hours</title>
          <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="3.18"/>
                    <measurement group_id="O2" value="3.97" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score Post-op Day 2</title>
        <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>2 days post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score Post-op Day 2</title>
          <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="2.06"/>
                    <measurement group_id="O2" value="4.17" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score Post-op Day 3</title>
        <description>Pain scale, where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>3 days post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score Post-op Day 3</title>
          <description>Pain scale, where 0 = no pain and 10 = worst pain imaginable</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.26"/>
                    <measurement group_id="O2" value="4.07" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NRS Pain Score Post-op Day 14</title>
        <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
        <time_frame>Post-Operative Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>NRS Pain Score Post-op Day 14</title>
          <description>Pain scale (0-10), where 0 = no pain and 10 = worst pain imaginable</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="2.58"/>
                    <measurement group_id="O2" value="2.07" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
        <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
        <time_frame>Post-Operative Day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
          <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="2.58"/>
                    <measurement group_id="O2" value="4.31" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
        <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
        <time_frame>Post-Operative Day 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
          <description>The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="2.71"/>
                    <measurement group_id="O2" value="3.94" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
        <description>at time of post-op visit The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
        <time_frame>Post-Operative Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life as Measured by the Brief Pain Inventory (BPI)</title>
          <description>at time of post-op visit The brief pain inventory scale uses the 0 to 10 numerical rating scale to measure pain intensity under four different conditions. On the four conditions 0 = no pain, no relief, and does not interfere, whereas 10 = pain as bad as you can imagine, complete relief, and completely interferes</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="2.61"/>
                    <measurement group_id="O2" value="1.65" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Use Prior to Hospital Discharge</title>
        <description>Oral morphine equivalent of opioid use while in the hospital</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Use Prior to Hospital Discharge</title>
          <description>Oral morphine equivalent of opioid use while in the hospital</description>
          <units>mg (oral morphine equivalents)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216" lower_limit="75" upper_limit="810"/>
                    <measurement group_id="O2" value="266" lower_limit="54" upper_limit="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Use End of Post-op Day 3</title>
        <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
        <time_frame>72 hrs post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Use End of Post-op Day 3</title>
          <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
          <units>mg (oral morphine equivalents)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="115" upper_limit="766"/>
                    <measurement group_id="O2" value="344" lower_limit="84" upper_limit="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Opioid Use at Post-op Day 14</title>
        <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
        <time_frame>Post-Operative Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Total Opioid Use at Post-op Day 14</title>
          <description>Total use of home opioids by pill count/ oral morphine equivalents</description>
          <units>mg (oral morphine equivalents)</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360" lower_limit="115" upper_limit="1086"/>
                    <measurement group_id="O2" value="443" lower_limit="84" upper_limit="1234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <time_frame>Post-Operative Day 14</time_frame>
        <population>if a patient reported a particular adverse effect at more than one time point, the patient was counted only once. Patients may report more than one adverse effect. Analysis and percentages reflect only those with complaints of adverse effects.</population>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine</title>
            <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine HCl</title>
            <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <population>if a patient reported a particular adverse effect at more than one time point, the patient was counted only once. Patients may report more than one adverse effect. Analysis and percentages reflect only those with complaints of adverse effects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Gas distension/bloated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat/cough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine</title>
          <description>extended-release bupivacaine (EXPAREL)&#xD;
Liposomal Bupivacaine: pre-incision infiltration with liposomal bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine HCl</title>
          <description>short-acting bupivacaine&#xD;
Bupivacaine HCl: pre-incision infiltration with bupivacaine HCl</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>study published in JMIG. https://doi.org/10.1016/j.jmig.2016.11.002</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kenneth I Barron</name_or_title>
      <organization>Center for Advanced Gynecology, PLLC</organization>
      <phone>5088876896</phone>
      <email>kenneth.barron.md@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

